Does bone morphogenetic protein increasethe incidence of perioperative complicationsin spinal fusion?: A comparison of 55,862 cases of spinal fusion with and without bone morphogenetic protein

Spine

Volumn 36, Issue 20, 2011, Pages 1685-1691

  Williams, Brian J ^a   Smith, Justin S ^a   Fu, Kai Ming G ^a   Hamilton, D Kojo ^b   Polly Jr , David W ^c   Ames, Christopher P ^d   Berven, Sigurd H ^e   Perra, Joseph H ^f   Knapp Jr , Dennis R ^g   McCarthy, Richard E ^h   Shaffrey, Christopher I ^a  

^a UNIVERSITY OF VIRGINIA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f TWIN CITIES SPINE CENTER   (United States)

^g Arnold Palmer Children's Hospital   (United States)

^h Jackson T Stephens Spine and Neurosciences Institute   (United States)

Author keywords

BMP; complication; scoliosis; spinal fusion; spondylolisthesis

Indexed keywords

BONE MORPHOGENETIC PROTEIN;

ADULT; AGE; ANTERIOR SPINE FUSION; ARTICLE; BRAIN ISCHEMIA; CERVICAL SPINE; CONTROLLED STUDY; EPIDURAL HEMATOMA; FEMALE; HEART ARRHYTHMIA; HUMAN; KYPHOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE COMPLICATION; POSTERIOR SPINE FUSION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RETROSPECTIVE STUDY; SCOLIOSIS; SEROMA; SPINE FUSION; SURGICAL INFECTION; THORACOLUMBAR SPINE; WOUND INFECTION;

ADOLESCENT; ADULT; AGED; BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; DATABASES, FACTUAL; HUMANS; INCIDENCE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SOCIETIES, MEDICAL; SPINAL DISEASES; SPINAL FUSION; YOUNG ADULT;

EID: 80052655961     PISSN: 03622436     EISSN: 15281159     Source Type: Journal    
DOI: 10.1097/BRS.0b013e318216d825     Document Type: Article

References (21)

1. Urist MR, Huo YK, Brownell AG, et al. Purification of bovine bone morphogenetic protein by hydroxyapatite chromatography. Proc Natl Acad Sci USA 1984; 81 (2): 371-5. (Pubitemid 14185731)
2. Food and Drug Administration. Food and Drug Administration Web site. http://www.fda.gov/MedicalDevices/ProductsandMedical Procedures/ DeviceApprovalsandClearances/Recently-Approved Devices/ucm083432.htm. Accessed 6/15/2010.
3. Food and Drug Administration. Food and Drug Administration Web site. http://www.fda.gov/MedicalDevices/ProductsandMedi-calProcedures/ DeviceApprovalsandClearances/Recently-Approved-Devices/ucm081181.htm. Accessed 6/15/2010.
4. Burkus JK, Sandhu HS, Gornet MF, et al. Use of rhBMP-2 in combination with structural cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery. J Bone Joint Surg Am 2005; 87 (6): 1205-12.
5. Glassman SD, Carreon LY, Campbell MJ, et al. The perioperative cost of Infuse bone graft in posterolateral lumbar spine fusion. Spine J 2008; 8 (3): 443-8. (Pubitemid 351608965)
6. Buttermann GR. Prospective nonrandomized comparison of an allograft with bone morphogenic protein versus an iliac-crest autograft in anterior cervical discectomy and fusion. Spine J 2008; 8 (3): 426-35.
7. Dickerman RD, Reynolds AS, Morgan BC, et al. rh-BMP-2 can be used safely in the cervical spine: dose and containment are the keys ! Spine J 2007; 7 (4): 508-9. (Pubitemid 47040676)
8. McClellan JW, Mulconrey DS, Forbes RJ, et al. Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2). J Spinal Disord Tech 2006; 19 (7): 483-6. (Pubitemid 44526745)
9. Poynton AR, Lane JM. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine (Phila Pa 1976) 2002; 27 (16)(suppl 1): S40-8.
10. Pradhan BB, Bae HW, Dawson EG, et al. Graft resorption with the use of bone morphogenetic protein: lessons from anterior lumbar interbody fusion using femoral ring allografts and recombi-nant human bone morphogenetic protein-2. Spine (Phila Pa 1976) 2006; 31 (10): E277-84.
11. Smucker JD, Rhee JM, Singh K, et al. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine. Spine (Phila Pa 1976) 2006; 31 (24): 2813-9. (Pubitemid 44772783)
12. Tumialan LM, Pan J, Rodts GE, et al. The safety and efficacy of anterior cervical discectomy and fusion with polyetheretherketone spacer and recombinant human bone morphogenetic protein-2: a review of 200 patients. J Neurosurg Spine 2008; 8 (6): 529-35. (Pubitemid 351830238)
13. Vaidya R, Carp J, Sethi A, et al. Complications of anterior cervical discectomy and fusion using recombinant human bone morphoge-netic protein-2. Eur Spine J 2007; 16 (8): 1257-65. (Pubitemid 350104617)
14. Villavicencio AT, Burneikiene S, Nelson EL, et al. Safety of trans-foraminal lumbar interbody fusion and intervertebral recombi-nant human bone morphogenetic protein-2. J Neurosurg Spine 2005; 3 (6): 436-43.
15. Haid RW Jr, Branch CL Jr, Alexander JT, et al. Posterior lumbar interbody fusion using recombinant human bone morpho-genetic protein type 2 with cylindrical interbody cages. Spine J 2004; 4 (5): 527-38; discussion 538-9. (Pubitemid 40029169)
16. Joseph V, Rampersaud YR. Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis. Spine (Phila Pa 1976) 2007; 32 (25): 2885-90. (Pubitemid 351339361)
17. Wong DA, Kumar A, Jatana S, et al. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J 2008; 8 (6): 1011-8.
18. Cahill KS, Chi JH, Day A, et al. Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA 2009; 302 (1): 58-66.
19. Boakye M, Mummaneni PV, Garrett M, et al. Anterior cervical discectomy and fusion involving a polyetheretherketone spacer and bone morphogenetic protein. J Neurosurg Spine 2005; 2 (5): 521-5.
20. Lanman TH, Hopkins TJ. Early findings in a pilot study of anterior cervical interbody fusion in which recombinant human bone mor-phogenetic protein-2 was used with poly(L-lactide-co-D,L-lactide) bioabsorbable implants. Neurosurg Focus 2004; 16 (3): E6.
21. Shields LB, Raque GH, Glassman SD, et al. Adverse effects associated with high-dose recombinant human bone morphogenetic pro-tein-2 use in anterior cervical spine fusion. Spine (Phila Pa 1976) 2006; 31 (5): 542-7.